Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. - Wikidata - wikimedia - TriplyDB

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

http://www.wikidata.org/entity/Q30828178

about

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications Nivolumab in melanoma: latest evidence and clinical potential Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland Antibody Therapies in Cancer.The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Genomic Classification of Cutaneous Melanoma Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials.Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.The immune escape in melanoma: role of the impaired dendritic cell function.New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.Single versus combination immunotherapy drug treatment in melanoma.Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).Harnessing the immune system for the treatment of melanoma: current status and future prospects.Biomarkers associated with checkpoint inhibitors.Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials Immune checkpoint inhibitors: a milestone in the treatment of melanoma.Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.What have we learned from cancer immunotherapy in the last 3 years?Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Targeted therapies in melanoma.Characterizing expanded access and compassionate use programs for experimental drugs.Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?Awakening immunity against cancer: a 2017 primer for clinicians.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.

P2860

Q26775546-9DA4150C-2858-4D8D-8A65-713CA1F7D96B Q28258598-5EB4D94C-3248-4E19-8560-E586DDF72251 Q30491702-3BE925E4-DC36-412A-B962-72B71F5BA084 Q31104000-D323564A-1DF8-43DE-8FCB-9DC4619099FB Q34402325-91EFF1E3-F919-442B-8817-6955749468D2 Q34667825-58E3CA61-0D64-476B-88C2-96F4F6064B78 Q34670776-CCEFB4EE-E2EC-4A65-9FDB-74C964AAF0A3 Q35794989-FE39CDB4-B801-4742-A3E8-C1AAD03F2B31 Q35798996-B5636AC5-B775-4F96-AE04-C05586CDF962 Q36028546-F2DBE9EE-B2B9-4A9D-9117-4B953572C07E Q36086834-C4B3FDF1-EF44-4237-B43A-55E5637B3F75 Q36256712-98B4DD8B-03E5-44B2-814A-18DEBA238470 Q36343040-70A3D462-B8CB-4D15-AF8D-09A04A94E7B8 Q36716229-21437B52-0F2F-410D-8789-7EF471746F75 Q36785750-864D6970-3D67-42E2-8737-52F9698AC5D9 Q37131014-8BF896F7-CC25-4A06-B367-79FFC669FDBF Q37265479-B938BCE4-CAFD-4850-B386-20B1479FED6E Q37380454-5CCB184F-2D63-4B4A-92D4-7F09B81F98AA Q37606693-D60854E6-CC96-46AA-82C0-A7E03AAF3AEF Q38250071-DA7CF004-16BC-484C-A61D-390B84359D9E Q38632728-5F0BBB29-C1CB-48DA-9CDB-BB9D420E9FD2 Q38661099-CBF04499-B2B9-404F-BD9B-80641D451A90 Q38773770-8AD934FA-21BE-4513-979A-E5C2C7CFEED6 Q38806243-9966E061-6980-4179-BA04-58AA0AC11507 Q38819537-FDCAA438-A4C6-44BB-9B56-00C62ECD67F1 Q38831830-1E70DC55-86A6-4FF1-A40C-1528E603CBE3 Q38845833-E02609B1-3A81-4BA9-9F14-B634A7E0FB90 Q38846255-26C3C36E-9359-492A-AB86-63EADE9CA878 Q39009781-E50E75A8-44DC-46F3-A6BC-514F14236C67 Q39532055-E0F3E3B8-C332-4FD6-96A0-C965EACEBBEC Q40065733-FCF3D629-86DA-4BE8-8225-58427744E5F2 Q40070782-57526330-2833-4298-BD31-8CC5F3BF1603 Q40226135-022B902B-7717-4FA0-A565-A570C6041DF9 Q40964128-3F846011-ACBC-4BA0-BE14-CC31D3D21652 Q41268316-E72B436B-D58A-4F3B-8396-974E66D3E27A Q42184966-85C7234D-5F94-4DB2-972E-EBA89CCFEC82 Q42343743-6642BFDF-9D73-4F11-A211-A89816B00AB3 Q42347636-0588C9EE-596C-440D-ADA4-E5964853F753 Q42375254-7501E95B-42B2-4783-961E-7E5EBBF949A8 Q45901589-8A5EE0B3-6545-46AE-BE2B-1C13865FDBF3

P2860

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

http://www.wikidata.org/entity/Q30828178

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical experience with ipili ...... anded access programme cohort.

@ast

Clinical experience with ipili ...... anded access programme cohort.

@en

type

label

Clinical experience with ipili ...... anded access programme cohort.

@ast

Clinical experience with ipili ...... anded access programme cohort.

@en

prefLabel

Clinical experience with ipili ...... anded access programme cohort.

@ast

Clinical experience with ipili ...... anded access programme cohort.

@en

P1433

Q30828178-A2575F6E-84B3-4F90-BDE1-6CE766111FD5

P1476

Q30828178-17290135-C8CB-44B4-9A25-108BBFF129B4

P2093

Q30828178-12ADF564-7EEC-4217-8EF6-916F2C9CFD01

Q30828178-4B52EBF2-8C93-487F-9F6A-ED0BE3C57F10

Q30828178-619EE6A5-604B-4863-ACA8-8BEEFBB73228

Q30828178-62762CAD-2BE3-4D04-BB7D-3DAB70D00F3C

Q30828178-634F00A0-ECCF-4EE8-8A46-5E1633C3B167

Q30828178-6E8CCFC6-123F-4DAF-882A-D915E9F331E2

Q30828178-85BF1A76-A7DD-4F01-95EE-A0B16C41D1DF

Q30828178-A163DAB4-FFB2-408A-ADDF-EADF41AA3DD4

Q30828178-C7DA0108-8705-48E3-B82E-638BE5C3E751

Q30828178-DD97E9F0-1C2A-483C-B67D-9D9612E32991

P2860

Q30828178-04ADF0E4-FB6E-4AD0-93E7-BB3C427F8D88

Q30828178-0725D9BE-5076-4A85-8B72-54C131AA68FB

Q30828178-12002431-567A-40B1-8CE8-EB6BD4488F59

Q30828178-25C4A366-C7ED-443E-B7D2-7B8D1456753E

Q30828178-306817E7-061C-4FB1-B8AE-F97EFD5DC970

Q30828178-30BC3DD1-A9EB-4619-BB68-EB9B299EB9B0

Q30828178-32622CCD-6B68-48AA-A545-FE3FD299785B

Q30828178-48EA348A-CC4F-4126-B3C4-4A4C0EA31D95

Q30828178-4A0507F2-F676-4341-A434-55CD5D3A792B

Q30828178-736D85B9-1A0C-4187-AD5D-DD12354311F5

P2888

Q30828178-382A85F3-D6D4-4740-BB1E-713AAF0EBE67

P304

Q30828178-9C40F175-B751-4235-9183-0EA9546F7BA9

P31

Q30828178-D1BA6163-48D0-4B20-8206-D0B9533965E9

P356

Q30828178-4FECB11C-05D2-4537-84CA-A38676FCDB22

P478

Q30828178-8792D411-C050-45F1-B615-D46215E630B3

P50

Q30828178-1BB87BB8-40D6-4336-A15E-6B0B385747C9

Q30828178-2646CC74-3159-4AA4-9699-2042DAFC73FA

Q30828178-70DB917D-2C4F-40CF-BD88-6A72DB619881

Q30828178-CEDD3489-85AC-4CDA-9D46-F58D7E624F73

Q30828178-D6B61CDB-5DC1-48A4-85B6-9F057AE7CFA3

Q30828178-E031475F-B735-42D2-B7B6-18AAC28F3259

Q30828178-F00CA787-D282-4C4D-905E-2095B04206AE

Q30828178-F4E21E3A-995E-4F0B-AC39-38E99F99731A

Q30828178-F7384068-D05A-46BF-BE81-B2FBBCB9A262

P577

Q30828178-EB692B24-3754-4631-AD1F-1A0E1A7BF0C0

P5875

Q30828178-0E24AB9F-1813-44A9-B01B-AF1CC611B382

P6179

Q30828178-96DD3897-3B18-4C3D-B151-68ACC71B880C

P698

Q30828178-E19D0B73-388F-41D4-B9A4-30E2BF54324F

P921

Q30828178-7ED94F89-7264-4930-83F1-E3AD0CD10E75

P932

Q30828178-90A8FB45-939F-467C-B5C3-A3056B4744CD

P356

1479-5876-12-116

P1433

Journal of Translational Medicine

P1476

Clinical experience with ipili ...... anded access programme cohort.

@en

P2093

Alessandro Testori

http://www.w3.org/2001/XMLSchema#string

Ester Simeone

http://www.w3.org/2001/XMLSchema#string

Francesco Cognetti

http://www.w3.org/2001/XMLSchema#string

Gaetana Rinaldi

http://www.w3.org/2001/XMLSchema#string

Maresa Altomonte

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Bernengo

http://www.w3.org/2001/XMLSchema#string

Mario Mandalà

http://www.w3.org/2001/XMLSchema#string

Michele Guida

http://www.w3.org/2001/XMLSchema#string

Riccardo Marconcini

http://www.w3.org/2001/XMLSchema#string

Ruggero Ridolfi

http://www.w3.org/2001/XMLSchema#string

P2860

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Improved survival with MEK inhibition in BRAF-mutated melanoma

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

P2888

1479-5876-12-116

P304

116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-12-116

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Antonio Ascierto

Michele Del Vecchio

Paolo Marchetti

Lorenza Di Guardo

Carolina Cimminiello

P577

2014-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262781363

http://www.w3.org/2001/XMLSchema#string

P6179

1049608203

http://www.w3.org/2001/XMLSchema#string

P698

24885479

http://www.w3.org/2001/XMLSchema#string

P921

P932

4030525

http://www.w3.org/2001/XMLSchema#string